QLQing Li

Qing Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qing Li has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Zhengsheng Chen

    Institute of Microsurgery on Extremities Department of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China

    4 shared publications
  • Yang Wang

    Institute of Microsurgery on Extremities, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China

    3 shared publications
  • Ji Yuan

    Institute of Microsurgery on Extremities, Department of Orthopedic Surgery, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications
  • Jiashuo Liu

    Department of Orthopedic Surgery Institute of Microsurgery on Extremities Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai Jiao Tong University Shanghai China

    2 shared publications
  • Rongrong Cao

    Institute of Microsurgery on Extremities Department of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China

    2 shared publications
  • Xin Niu

    Institute of Microsurgery on Extremities, Department of Orthopedic Surgery, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    2 shared publications

Latest Publications

  • Open Access

    Factors Associated With Accelerated Fracture Healing in Patients With Traumatic Brain Injury and Extremity Comminuted Fractures: A Retrospective Case–Control Study

    by Xueqian Li, Rongrong Cao, Cheng Wang, Zhengsheng Chen, Jieyuan Zhang, Qing Li, Xin Ma

    Objective: Although traumatic brain injury (TBI) has been clinically associated with accelerated bone healing, the factors that determine which patients experience this phenomenon remain poorly defined, and previous findings are conflicting. This study aimed to investigate the clinical factors associated with accelerated fracture healing in patients with TBI combined with comminuted fractures of the limbs, so as to provide an evidence‐based foundation for elucidating the clinical phenomenon of TBI‐promoted fracture healing. Methods: A retrospective case–control study design was employed. Patients between January 2020 and April 2024 with concurrent diagnoses of TBI and comminuted fractures were included. Based on radiographic findings and RUST/mRUST scores, patients were divided into an accelerated healing group (AHG) and a normal/delayed healing group (NDHG). Clinical data including demographics (age, sex, BMI), TBI characteristics (injury site, GCS score), admission laboratory indices (blood count, coagulation function, inflammatory markers), and fracture site/local soft tissue conditions, as well as functional outcomes assessed by the Short Musculoskeletal Function Assessment (SMFA) questionnaire at final follow‐up were collected. Univariate analysis and multivariate logistic regression analysis were used to identify independent factors influencing accelerated fracture healing. Receiver operating characteristic (ROC) curves were plotted to evaluate their predictive value. Results: A total of 119 patients were included, with 69 in the AHG and 50 in the NDHG. Significant differences were observed between the two groups in terms of age, BMI, GCS score, and platelet count ( p < 0.05). Univariate analysis showed that age, BMI, GCS score, red blood cell count, and platelet count were associated with accelerated fracture healing ( p < 0.20). Multivariate logistic regression analysis indicated that younger age (OR = 0.875, 95% CI: 0.821–0.934) and lower GCS score (indicating more severe TBI; OR = 0.490, 95% CI: 0.339–0.707) were independent predictors of accelerated fracture healing. ROC curve analysis showed that the area under the curve (AUC) for age and GCS score in predicting accelerated healing were 0.893 and 0.851, respectively. Conclusions: In patients with TBI combined with comminuted fractures, younger age and greater TBI severity (lower GCS score) are independent predictors of accelerated fracture healing. These findings assist clinicians in the early identification of patients with high healing potential to optimize treatment strategies, facilitate the early identification of high‐risk patients, and provide clinical clues for further exploration of the molecular mechanisms underlying neurohumoral regulation of bone regeneration.

  • Open Access

    iPSCs derived sEVs ameliorate NK cell senescence by targeting CISH-STAT3

    by Yu Chen, Rongrong Cao, Zhengsheng Chen, Juntao Zhang, Yajing Ren, Xin Niu, Ji Yuan, Lei Luo, Shuxiang Yu, Yang Wang, et al.

    Natural killer (NK) cells, essential components of the innate immune system, undergo subtype changes with aging that diminish their cytotoxic and tumor surveillance functions. Recent reports indicate that small extracellular vesicles (sEVs) derived from stem cells could ameliorate age-related diseases, while their effects on NK cell senescence remain unexplored. We administered induced pluripotent stem cell(iPSC) derived sEVs via tail vein injection for 6 months to naturally aged mouse models. Then we detected a senescent phenotype of splenic NK cells based on a series recognized markers in aged mice. To further investigate the impact of iPSC-sEVs mediated rejuvenation on NK cell function in vivo, purified splenic NK cells from iPSC-sEVs or vehicle-treated mice were co-injected subcutaneously with B16 tumor cells to establish co-inoculation models. In vitro, we used D-gal induced NK92 aged model and conducted transcriptome analysis on the cells. Furthermore, NK92 cells overexpressing CISH were used to explore the mechanism by which iPSC-sEVs improve NK92 cells senescence. Further we conducted a mass spectrometry analysis of the substances in iPSC-sEVs and performed bioinformatics analysis. iPSC-sEVs treatment partially reversed these immunosenescence phenotypes in aged mice models. In splenic NK and B16 tumor cells co-inoculation models, iPSC-sEVs-NK cells exhibited significantly enhanced cytotoxicity against tumor cells and the ability to recruit T cells. Mechanistic studies suggest that iPSC-sEVs inhibit the upregulation of CISH in senescent NK cells, subsequently activating p-STAT3, which is involved in regulating NK cell senescence and cytotoxicity. Overexpression of CISH significantly suppresses STAT3 phosphorylation and accelerates NK92 cell senescence. Proteomic analysis indicates that iPSC-sEVs modulate the CISH-STAT3 signaling pathway by delivering RNA binding proteins. In summary, our study shows that iPSC-sEVs effectively rejuvenate senescent NK cells by partially suppressing CISH expression and promoting STAT3 phosphorylation. As a cell-free therapeutic agent, iPSC-sEVs represent a promising strategy for treating cancer in the elderly and other inflammatory senescence-related diseases.


  • Open Access

    Identification of a specific marker panel for human mesenchymal stem cell‐derived small extracellular vesicles

    by Lei Luo, Zhengsheng Chen, Ji Yuan, Xin Niu, Jiashuo Liu, Chao Gu, Hong Xu, Chuncui Jia, Tao Na, Shufang Meng, et al.

    Human mesenchymal stem cell‐derived small extracellular vesicles (MSC‐sEVs) have demonstrated significant immunomodulatory and pro‐regenerative potentials. However, the lack of specific markers to define MSC‐sEVs presents a major challenge for their clinical application. Here, the proteomic datasets of MSC‐sEVs from three cell sources were synchronously analyzed, and several surface antigens commonly found on MSCs were selected as candidate markers due to their high abundances in MSC‐sEVs. Next, MSC‐sEVs from three cell sources (adipose tissue, umbilical cord, and induced pluripotent stem cells) were stained with fluorescein‐conjugated antibodies and analyzed by NanoFCM at single‐vesicle resolution. The positive rates of CD13, CD29, and CD90 all exceeded 60% across sEVs derived from three MSCs sources, whereas other candidates generally exhibited lower positive rates. The high positive rates of them were further verified in MSC‐sEVs purified via other methods. Moreover, high‐resolution microscopy, as an orthogonal method, visually validated their high presence in MSC‐sEVs. Meanwhile, none of the non‐MSC‐sEVs showed concurrent positive rates for CD13, CD29, and CD90 exceeding 40%, suggesting that this marker panel (with a positive rate threshold of 50% for all three markers) could specifically distinguish MSC‐sEVs from non‐MSC‐sEVs. Finally, the positive rates of this panel of markers were assessed in sEVs derived from MSCs at successive passages. The results revealed a progressive diminution of the positive rates of CD29 and CD90 in the sEVs secreted by MSCs with successive passages, accompanied by a reduction in the pro‐proliferative activity of these sEVs. Taken together, we have identified a specific and quantifiable marker panel for MSC‐sEVs characterization, which facilitates the development of standardized assays for defining MSC‐sEVs and ultimately accelerates the clinical translation of MSC‐sEVs.


  • Top Cited Papers
    Open Access

    Engineered MSC‐sEVs as a Versatile Nanoplatform for Enhanced Osteoarthritis Treatment via Targeted Elimination of Senescent Chondrocytes and Maintenance of Cartilage Matrix Metabolic Homeostasis

    by Kai Feng, Jiashuo Liu, Liangzhi Gong, Teng Ye, Zhengsheng Chen, Yang Wang, Qing Li, Xuetao Xie

    Chondrocyte senescence is an important pathogenic factor causing osteoarthritis (OA) progression through persistently producing pro‐inflammatory factors. Mesenchymal stem cells‐derived small extracellular vesicles (MSC‐sEVs) have shown anti‐inflammatory effects in OA models, while persistent existence of senescent chondrocytes still promotes cartilage destruction. Therefore, improving the targeted elimination ability on senescent chondrocytes is required to facilitate the translation of MSC‐sEVs in OA treatment. In this study, versatile engineered MSC‐sEVs are developed to targetedly clear senescent chondrocytes and maintain cartilage metabolic homeostasis. Specifically, MSC‐sEVs are loaded with siRNA mouse double minute 2 homologue (siMDM2) and modified with cartilage‐targeting peptide WYRGRL‐PEG2K‐DSPE (WPD), named WPD‐sEVssiMDM2. The results demonstrate versatile modification improves the cellular uptake of MSC‐sEVs in chondrocytes, and thus improves the antiaging effects. Importantly, multifunctional modification enhances cartilage penetration ability and extends joint retention time of MSC‐sEVs. In both post‐traumatic OA mice and naturally aged mice, WPD‐sEVssiMDM2 more effectively eliminates senescent chondrocytes and maintained matrix metabolic homeostasis. By using the P53 phosphorylation inhibitor, the essential role MDM2‐P53 pathway in the antiaging function of WPD‐sEVssiMDM2 on chondrocytes is verified. In ex vivo cultured human OA cartilage explants, it is confirmed that WPD‐sEVssiMDM2 alleviates senescent phenotype. Altogether, the findings suggest that WPD‐sEVssiMDM2 have promising translational potential for OA treatment.